Cannazo India

Sukrit Goel is Season 3's most personally medically transformed founder. He suffered a brain haemorrhage and recovered with the help of cannabis-based medication, an experience that fundamentally transformed his understanding of the plant's therapeutic potential and became the founding mission of Cannazo India. The brand finds its philosophical roots in India's most ancient text: the Atharva Veda (Book 11, Hymn 8) mentions hemp (bhang) as one of five sacred plants, establishing that cannabis-based medicine is not a Western import but an indigenous Indian healing tradition dating back over 3,000 years.

Cannazo India is India's most comprehensively formulated medical cannabis brand, producing 30 plus AYUSH-Ministry-approved Vijaya (cannabis leaf) based formulations that combine ancient Ayurvedic healing principles with modern biotechnology, nanotechnology-enhanced delivery systems, and NABL-accredited lab testing to deliver safe, effective, and clinically validated cannabis-based healthcare products. The product range addresses a wide spectrum of health conditions: cancer pain management, insomnia, anxiety, depression, epilepsy, autism spectrum disorder, chronic inflammation, arthritis, menstrual discomfort, post-chemotherapy pain, and neurological disorders. The dual prescription-only (60%) and over-the-counter (40%) product structure ensures appropriate medical oversight for high-potency formulations while making general wellness products accessible without prescriptions.

Amount Asked: ₹1.5 crore Equity Offered: 5% Implied Pre-Money Valuation: ₹30 crore

Sukrit, Kartik, and Arzoo walked into Season 3 Episode 21 as India's first medical cannabis founders to appear on Shark Tank, making the pitch historically significant for the Indian cannabis wellness industry before a single product was demonstrated. Sukrit opened with his deeply personal brain haemorrhage recovery story, establishing the emotional credibility that a medical cannabis pitch needed to overcome the immediate stigma association. The founders highlighted the medicinal properties of cannabis, its Vedic origins in Indian culture, and the legal distinction between banned flowering tops and permitted leaf-based medicines. They demonstrated their product range, the AYUSH approvals, NABL lab testing, and the CSIR research partnership, building institutional credibility layer by layer.

Anupam Mittal exited first, citing that Cannazo lacked both front-end consumer infrastructure and back-end distribution scale. Aman Gupta exited citing a conflict of interest. He appreciated the business concept but could not invest due to portfolio considerations. Azhar Iqubal (guest Shark) asked about distribution splits and market size but exited because he lacked sufficient domain knowledge to evaluate the scientific claims confidently, particularly around the 80 to 85% product efficacy claim. Peyush Bansal saw strong potential in the business and appreciated the founders' backgrounds. Vineeta Singh had prior familiarity with the medical cannabis category and asked about founder backgrounds and scientific evidence.

Namita Thapar offered ₹25 lakhs for 2% equity in a solo bid. Vineeta and Peyush jointly offered ₹50 lakhs for 4% equity plus 2% royalty until ₹2 crore recouped, with the condition that the founders must include proportional equity from Hexorp Nanotech (manufacturing company) in the deal. The founders declined Namita's solo offer and accepted Vineeta and Peyush's conditional joint offer. The Hexorp equity condition was the deal's most commercially significant structural negotiation point: Vineeta and Peyush insisted on it to prevent the founders from keeping manufacturing profits in a separate entity while the Shark-invested brand entity bore marketing and distribution costs.

Sukrit Goel, Kartik Sharma, and Arzoo Puri accepted Vineeta Singh and Peyush Bansal's joint offer of ₹50 lakhs for 4% equity plus 2% royalty until ₹2 crore is recouped, with the condition that Hexorp Nanotech equity must be included in the deal structure. The deal brought SUGAR Cosmetics' consumer brand expertise (Vineeta) and Lenskart's health and wellness distribution methodology (Peyush) into India's first Shark Tank-featured medical cannabis company.

Cannazo India's appearance on Shark Tank India marked a watershed moment for the Indian medical cannabis industry: national television broadcast of a medical cannabis brand's pitch, deal negotiation, and investment normalised the conversation around cannabis-based healthcare in India to an extent that no marketing campaign could have achieved. The company secured a consultancy tie-up with CSIR (Council of Scientific and Industrial Research), India's premier research body, adding the most institutionally prestigious research partnership available for a medical cannabis company. The product range has expanded to include gummies, RSO (Rick Simpson Oil), liposomal berberine, and hemp seed oil softgels, broadening the addressable market beyond prescription-only cannabis formulations. The "As Seen on Shark Tank India" branding on the website and at The Lil Flea (Mumbai consumer event, April 2024) continues converting the national broadcast visibility into consumer credibility.